^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BCL2 expression

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Entrez ID:
6d
Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Primary EN-DLBCL can involve multiple organs or tissue sites. TP53 , MYD88 , and CD79B are the most common gene mutations. The efficacy of BTKi in patients with positive MCD subtypes at intermediate and high risk is not inferior to that in MCD-negative control patients.
Retrospective data • Journal • IO biomarker
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule)
|
TP53 mutation • BCL2 expression • MYC expression • CD79B mutation • CD79B mutation
|
Rituxan (rituximab) • lenalidomide
6d
Curcumol Mediates the Programmed Cell Death in Acute Myeloid Leukemia through PI3K/AKT Signaling Pathway (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Curcumol may mediate the programmed death of AML cells by inhibiting the PI3K/AKT signaling pathway, affecting the expression of Bcl-2 family proteins, and promoting the activation of core members of Caspase family, so as to play an anti-leukemia role.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CASP6 (Caspase 6, apoptosis-related cysteine peptidase)
|
BCL2 expression • BAX expression
8d
Adenosine deaminase acting on RNA 2 provides neuroprotection by activating Kv1.1 channels in a rat epilepsy model. (PubMed, Cytojournal)
A rat epilepsy model was induced in vivo using lithium chloride-pilocarpine...In the recovery experimental group that involved silencing Kv1.1, the beneficial effects of overexpressing ADAR2 were no longer observed (P < 0.05). Our findings confirm that the upregulation of ADAR2 promotes Kv1.1 protein expression, which ultimately reduces neuronal damage in the hippocampus of animals with epilepsy.
Preclinical • Journal • IO biomarker
|
NUP98 (Nucleoporin 98 And 96 Precursor 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ADAR (Adenosine Deaminase RNA Specific) • CASP7 (Caspase 7) • ADARB1 (Adenosine Deaminase RNA Specific B1)
|
BCL2 expression • ADAR overexpression
8d
Effect of Petiveria alliacea leaf extract and its active components on heart muscle cell apoptosis induced by hyperglycemia. (PubMed, Open Vet J)
In addition, the results showed that isoarborinol acetate and myricitrin compounds have inhibition of alpha-glucosidase and caspase-3. It can be concluded that EEPa is one of the alternative choices to overcome hyperglycemia.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression
9d
Excess Ub-K48 Induces Neuronal Apoptosis in Alzheimer's Disease. (PubMed, J Integr Neurosci)
Ub-K48 is strongly linked to the development of AD. p-Tau aggregate in neuronal cells in the hippocampal region of the AD brain and colocalize with Ub-K48, which in turn leads to cellular inflammation and the induction of apoptosis in neuronal cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FAP (Fibroblast activation protein, alpha) • GFAP (Glial Fibrillary Acidic Protein)
|
BCL2 expression • BCL2/BAX ratio elevation
10d
Impact of cataranthine treatment on miRNA34 and miRNA29 levels in HepG2 cells and their association with the expression levels of Bcl-2 and Nrf2. (PubMed, Mol Biol Rep)
These findings suggest that cataranthine may exert its anticancer effects by reducing oxidative stress and promoting apoptosis, while decrease in miR34 and miR29 as well as increase in Nrf2 and Bcl2 may act as resistance mechanisms in cancer cells. The results highlight the dual potential of cataranthine in regulating cellular responses to oxidative stress and cell death in liver cancer, with dose-dependent modulatory effects.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • MIR34A (MicroRNA 34a-5p) • MIR29A (MicroRNA 29a)
|
BCL2 expression
11d
Integrating UPLC-MS/MS Bioinformatics and In Vivo Experiments Validation to Elucidate the Mechanism of Wenzi Jiedu Decoction in Suppressing Colorectal Cancer. (PubMed, Phytochem Anal)
This study indicated that the potential mechanism of WJD in the prevention and treatment of CRC had the characteristics of the multi-target, multi-path, and multi-system mechanisms, which were mainly related to the regulation of chemokines and the promotion of apoptosis.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • BCL2L1 (BCL2-like 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD4 (CD4 Molecule) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • CD8 expression • BAX expression • CXCL8 expression
11d
Retrospective data • Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
12d
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P3, N=92, Active, not recruiting, National Cancer Institute (NCI) | N=302 --> 92 | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Jun 2024
Enrollment change • Trial completion date • Trial primary completion date
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TNFA (Tumor Necrosis Factor-Alpha) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD79A (CD79a Molecule) • GSTT1 (Glutathione S-transferase theta 1)
|
BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation
|
Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
12d
Malignant behaviors and immune response in melanoma: Epstein-Barr virus induced gene 3 as a therapeutic target based on an in-vitro exploration. (PubMed, PeerJ)
Meanwhile, EBI3 knockdown diminished the phosphorylation levels of both Smad3 and STAT6 and the levels of immune response-relevant cytokines in melanoma cells, while aggravating the macrophage M1 polarization and the expression of cGAS, p-STING and p-IRE1 α in THP-1 monocyte-derived macrophages co-cultured with EBI3-silenced melanoma cells. This study filled the blank on the involvement of EBI3 in melanoma, hinting the possibility of controlling EBI3 as a therapeutic strategy in the management of melanoma.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • STING (stimulator of interferon response cGAMP interactor 1) • CDH2 (Cadherin 2) • STAT6 (Signal transducer and activator of transcription 6) • CGAS (Cyclic GMP-AMP Synthase) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • SMAD3 (SMAD Family Member 3)
|
BCL2 expression • CDH1 expression
12d
GANT61 surmounts drug resistance of ADR by upregulating lysosome activities and reducing BCL2 expression in HL-60/ADR cells. (PubMed, Cancer Cell Int)
GANT61 effectively reversed ADR resistance in HL-60/ADR cells by upregulating lysosome activities and downgrading BCL2 expression, providing a new treatment strategy with acceptable toxicity for AML-resistant patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • GLI1 (GLI Family Zinc Finger 1)
|
BCL2 expression
|
Venclexta (venetoclax) • doxorubicin hydrochloride
12d
Luteolin inhibits proliferation of lung cancer A549 cells by increasing ROS production and inhibiting the AKT/mTOR signaling pathway and HO-1 expression (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
Luteolin induces apoptosis and autophagy to inhibit proliferation of A549 cells by increasing ROS production, inhibiting the AKT/mTOR pathway and down-regulating HO-1 protein expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
12d
Alogliptin attenuates testicular damage induced by monosodium glutamate in both juvenile and adult male rats by activating autophagy: ROS Dependent AMPK/mTOR. (PubMed, Reprod Toxicol)
MSG induced more severe adverse testicular effects in juvenile rats, while ALO pretreatment was more protective in adult rats. ALO's anti-inflammatory, antioxidant, antiapoptotic, pro-autophagic, antifibrotic, and proliferative actions in the testis suggest its promising potential for combating male reproductive dysfunction.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • SQSTM1 (Sequestosome 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • BECN1 (Beclin 1)
|
BCL2 expression
13d
Production and functional analysis of a phage displayed scFv recombinant antibody targeting EGFR/HER2 dimerization domain. (PubMed, Protein Expr Purif)
The produced scFv antibody showed to be functional in a simultaneous blockade of EGFR and HER2, suggesting its potential as a promising candidate for targeted therapy against various EGFR overexpressing tumors.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
HER-2 expression • EGFR expression • BCL2 expression • BAX expression
|
Herceptin (trastuzumab)
13d
USP37 promotes diffuse large B-cell lymphoma progression by deubiquitinating and stabilizing c-myc. (PubMed, J Mol Histol)
Overexpressing c-myc, however, may partially counteract this impact. The data show that USP37 may be a potential therapeutic target for DLBCL, and that it may enhance the course of the disease by deubiquitinating c-myc via direct interactions with c-myc.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
14d
Role of TNFRSF12A in cell proliferation, apoptosis, and proinflammatory cytokine expression by regulating the MAPK and NF-κB pathways in thyroid cancer cells. (PubMed, Cytokine)
Treatment with PD98059, SP600125, SB203580, or Bay 11-7082 reversed the effects of TNFRSF12A overexpression on cell proliferation, apoptosis, and proinflammatory cytokine expression. In conclusion, the effects of TNFRSF12A on proliferation, apoptosis, and proinflammatory cytokine expression in THCA cells were regulated by the MAPK and NF-κB pathways.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • IL1B (Interleukin 1, beta) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
|
BCL2 expression • CCND1 expression • BAX expression
|
PD98059 • Bay11-7082 • SP600125
15d
Bcl‑xL‑specific BH3 mimetic A‑1331852 suppresses proliferation of fluorouracil‑resistant colorectal cancer cells by inducing apoptosis. (PubMed, Oncol Rep)
Furthermore, A‑1331852 suppressed the growth of xenograft tumors derived from 5‑FU‑resistant cells by inducing apoptosis. Overall, the present findings suggested that Bcl‑xL upregulation contributes to 5‑FU resistance of colorectal cancer and targeted inhibition by A‑1331852 may be an effective treatment strategy.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
BCL2 expression
|
5-fluorouracil • A-1331852
15d
Nanoparticle-enhanced delivery of resveratrol for targeted therapy of glioblastoma: Modulating the Akt/GSK-3β/NF-kB pathway in C6 glioma cells. (PubMed, Brain Res)
The findings suggest that RES effectively targets the AKT/GSK-3β/NF-kB signaling pathway in glioma cells. Furthermore, RES-loaded albumin nanoparticles significantly enhance therapeutic efficacy by improving cellular penetration, highlighting their potential in advancing GBM treatment strategies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
15d
Peptide Nanocarriers for Targeted Delivery of Nucleic Acids for Cancer Therapy. (PubMed, Bioconjug Chem)
Results demonstrated that this delivery system can be efficiently and selectively taken up by RGD receptor-positive cells (αvβ3 integrin receptor), further inducing effective target gene knockdown. Overall, this system provided a promising strategy for the targeted delivery of nucleic acid drugs.
Journal
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
16d
Overexpression of Growth Differentiation Factor 15 Reduces Neuronal Cell Damage Induced by Oxygen-Glucose Deprivation/Reoxygenation via Inhibiting Endoplasmic Reticulum Stress-Mediated Ferroptosis. (PubMed, Dev Neurobiol)
This study shows that overexpression of GDF15 reduces OGD/R-induced HT22 cell damage, and ER stress-mediated ferroptosis is included in the regulatory mechanisms. This provides a theoretical basis for GDF15 as a new target for the treatment of cerebral ischemia-reperfusion injury.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • GDF15 (Growth differentiation factor 15) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression • GDF15 overexpression
16d
Fluorescent Staining-Assisted Evaluation of the Anticancer Potential of Nyctanthes arbor-tristis Extracts in HepG2 Liver Cancer Cells. (PubMed, Luminescence)
Quantitative RT-PCR analysis showed increased Bcl2 gene expression with fold variation level of about 0.086094579. The obtained results emphasized the significance of Nyctanthes arbor-tristis extracts with a suggestion of chemotherapeutic medication to treat various cancers in the future.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
17d
SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression. (PubMed, Cell Biol Toxicol)
Thus, the TYK2/STAT3/Bcl2 axis is a crucial mechanism through which SS18-SSX mediates apoptosis evasion in SS cells. In conclusion, our findings contribute to understanding how SS18-SSX-driven TYK2 expression mediates apoptosis evasion mechanisms and propose targeting TYK2 as a strategy to induce apoptosis in SS.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TYK2 (Tyrosine Kinase 2) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
|
BCL2 expression
19d
Mechanism of kaempferol on intervertebral disc degeneration based on p38 MAPK signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
Activation of the p38 MAPK signaling pathway by anisomycin reduced the therapeutic effects of KAE. The study concluded that KAE could improve the proliferation activity of degenerated NPCs, reduce inflammation levels, and slow the progression of IDD in rats, and the mechanism was likely related to the regulation of the p38 MAPK signaling pathway.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL17A (Interleukin 17A) • MMP3 (Matrix metallopeptidase 3)
|
BCL2 expression • BAX expression
19d
Mechanism of aucubin in regulating ribosome biogenesis and inhibiting injury of nucleus pulposus cells and extracellular matrix degradation (PubMed, Zhongguo Zhong Yao Za Zhi)
PI3K inhibitor LY294002 intervention could reduce the promoting effect of AU on ribosome biogenesis. The above results suggest that AU can improve the injury of nucleus pulposus cells and ECM degradation, and its mechanism of action is related to its activation of the PI3K/mTOR pathway to promote ribosome biogenesis.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • ACAN (Aggrecan)
|
BCL2 expression • BAX expression
|
LY294002
19d
Rose roxburghii polysaccharide-induced apoptosis of prostate cancer DU145 cells by inhibiting PI3K/Akt/mTOR pathway and antioxidant effects (PubMed, Zhongguo Zhong Yao Za Zhi)
R. roxburghii polysaccharides may inhibit the proliferation of DU145 cells and induce its apoptosis by inhibiting the PI3K/Akt/mTOR pathway and clearing intracellular ROS.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BAX (BCL2-associated X protein)
|
BCL2 expression • PTEN expression • BAX expression
19d
Protective effect of Polygonati Rhizoma aqueous extract on gastric mucosal injury in mice induced by overtaking pungent substances and alcohol via TRAF1/ASK1/JNK pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
The results showed that the Polygonati Rhizoma aqueous extract alleviated the stomach Yin deficiency in mice, ameliorated gastric mucosal lesions, increased the activities of antioxidant enzymes in the gastric tissue(P<0.05, P<0.01), lowered the levels of pro-inflammatory cytokines in the gastric tissue(P<0.05, P<0.01), down-regulated the expression levels of proteins in the TRAF1/ASK1/JNK pathway(P<0.01) and pro-apoptotic factors in the gastric tissue, and up-regulated the expression of B-cell lymphoma-2(Bcl-2). The results suggested that the Polygonati Rhizoma aqueous extract could alleviate the symptoms of stomach Yin deficiency, such as hunger without desire to eat, thirst, and dry stool, and mitigate the gastric mucosal injury caused by overtaking pungent substances and alcohol by inhibiting the TRAF1/ASK1/JNK pathway to reduce apoptosis and inflammation in the gastric tissue.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • TRAF1 (TNF Receptor Associated Factor 1) • MAPK8 (Mitogen-activated protein kinase 8)
|
BCL2 expression
19d
Essential oil of Acori Tatarinowii Rhizoma inhibits pyroptosis of microglia by regulating NLRP3 inflammasomes (PubMed, Zhongguo Zhong Yao Za Zhi)
In addition, the essential oil inhibited the expression of Iba-1, lowered the levels of TNF-α, IL-1β, and IL-18, and down-regulated the mRNA levels of NLRP3, ASC, and caspase-1 as well as the protein levels of NLRP3, ASC, caspase-1, p-IKKβ(Y188)/IKKβ, p-NF-κB(S536)/NF-κB p65, cleaved caspase-1, and GSDMD-N. The results indicated that the essential oil of Acori Tatarinowii Rhizoma inhibited the NLRP3 inflammasome-mediated pyroptosis of microglia.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CASP1 (Caspase 1)
|
BCL2 expression • BAX expression
20d
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
20d
Tibetan golden acupuncture inhibits JNK/caspase-3 signaling pathway to alleviate neuronal apoptosis in cerebral ischemia-reperfusion injury. (PubMed, Heliyon)
The expression of B-cell lymphoma 2 (Bcl-2) was significantly increased (p < 0.01, p < 0.05). GA can restore neurological dysfunction and inhibit hippocampal neuronal apoptosis in CI/RI mice, at least partially through inhibition of the JNK/Caspase-3 signaling pathway and regulation of apoptosis signals.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
20d
DNA-mediated self-assembly oxidative damage amplifier combined with copper and MTH1 inhibitor for cancer therapy. (PubMed, Bioact Mater)
Meanwhile, the released functional nucleic acid G3139 downregulated the expression of Bcl-2, and accelerated the apoptosis of tumor cells. In conclusion, the HTCG@TA demonstrated significant effect in oxidative damage amplification and tumor inhibition both in vitro and in vivo, which has provided a new outlook for the clinical application of chemo-dynamic tumor treatment and synergistic gene therapy with self-delivery nanoplatforms.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
Genasense (oblimersen)
20d
Anticancer effects of alpha-lipoic acid, a potent organosulfur compound by modulating matrix metalloproteinases and apoptotic markers in osteosarcoma MG-63 cells. (PubMed, J Steroid Biochem Mol Biol)
Notably, ALA interacted directly with the active site of MMP2 and MMP9. These findings suggest that ALA has the potential to be a promising agent with anti-cancer effects on MG-63 cells, warranting further preclinical investigations.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
21d
miR-484 as an "OncomiR" in Breast Cancer Promotes Tumorigenesis by Suppressing Apoptosis Genes. (PubMed, Ann Surg Oncol)
Our results show that miR-484 may play a roll as an onco-miR in BC. Increased miR-484 and BCL2, and decreased Casp3, in breast tumor tissues suggest that Casp9 expression may increase uncontrolled cell proliferation by suppressing apoptosis in BC cells and may contribute to tumor progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KEAP1 (Kelch Like ECH Associated Protein 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • MIR484 (MicroRNA 484)
|
BCL2 expression
21d
How I diagnose high-grade B-cell lymphoma. (PubMed, Am J Clin Pathol)
High-grade B-cell lymphomas are subclassified based on morphologic and genetic features. There are differences in the nomenclature and definition of these lymphomas in the WHO-5 and ICC classifications. Distinguishing HGBLs from other mature B-cell lymphomas and B-LBL/ALL is critical so that patients receive appropriate treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL2 expression • MYC expression • MYC rearrangement + BCL6 rearrangement • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
21d
Ameliorative Effect of Ginsenoside Rc on 5-Fluorouracil-Induced Chemotherapeutic Intestinal Mucositis via the PI3K-AKT/NF-κB Signaling Pathway: In Vivo and In Vitro Evaluations. (PubMed, Int J Mol Sci)
Furthermore, Rc exerts anti-inflammatory and anti-apoptotic effects through PI3K-AKT and NF-κB signaling pathways. In conclusion, ginsenoside Rc demonstrated significant protective effects against 5-Fu-induced intestinal mucositis via the PI3K-AKT/NF-κB signaling pathway, suggesting its potential as a therapeutic agent for chemotherapy-related mucositis.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
|
5-fluorouracil
22d
Matrine promotes colorectal cancer apoptosis by downregulating shank-associated RH domain interactor expression. (PubMed, World J Gastrointest Oncol)
SHARPIN was identified as an upregulated anti-apoptotic protein in CRC, and matrine exhibited anticancer effects by downregulating its expression. Thus, matrine appears to be a promising drug for CRC.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8)
|
BCL2 expression
23d
Capecitabine regulates proliferation and apoptosis of ovarian cancer SKOV3 cells via the miR-29b-3p/MMP16 molecular axis. (PubMed, Am J Transl Res)
Capecitabine enhances miR-29b-3p expression, leading to the downregulation of MMP16, thereby inhibiting proliferation and promoting apoptosis in ovarian cancer cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP16 (Matrix Metallopeptidase 16)
|
BCL2 expression
|
capecitabine
23d
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients. (PubMed, Hemasphere)
Bcl-2 protein ratios predicting sensitivity to venetoclax in vitro were also able to distinguish patients with shorter time to progression after triplet-based induction therapy and ASCT. This is the first study to assess the expression of the most important Bcl-2 family proteins by a quantitative method in a large set of MM patients according to their cytogenetic abnormalities. We shed light on the impact of these proteins on MM prognosis, which could help to consider the levels of proteins involved in apoptosis in the development of new therapeutic strategies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • BBC3 (BCL2 Binding Component 3)
|
Chr t(11;14) • BCL2 expression
|
Venclexta (venetoclax)
23d
Docetaxel treatment together with CTLA-4 knockdown enhances reduction of cell viability and amplifies apoptosis stimulation of MCF-7 breast cancer cells. (PubMed, Cytotechnology)
The additive effect of CTLA-4 knockdown together with Docetaxel treatment significantly downregulated BCL-2 level and upregulated BAX expression. Our findings support the idea that combining chemotherapy such as Docetaxel with efficient targeted therapy against inhibitory immune checkpoints can be a promising strategy in cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
docetaxel
24d
Discovery of Voreloxin as a Dual-Selective Stabilizer for c-Myc/Bcl-2 G-Quadruplexes in Leukemia. (PubMed, Chem Biol Drug Des)
Molecular docking, molecular dynamics (MD) simulations, and MM/GBSA calculations further confirmed the stable binding of voreloxin to both c-Myc and Bcl-2 G4s, primarily driven by π-π stacking and hydrogen bonding interactions. These findings provide valuable insights for the development of G4-targeting drugs for cancer therapy.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
|
Qinprezo (vosaroxin)
25d
Deoxynivalenol induces spleen damage, apoptosis, and inflammation in mice by increasing mitochondrial reactive oxygen species: Protective effects of curcumin. (PubMed, Food Chem Toxicol)
Mitoquinone is a mitochondria-targeted antioxidant that can prevent of mitochondrial oxidative damage...Finally, we confirmed that Cur (50 or 100 mg/kg body weight) attenuated DON-induced apoptosis and inflammation by inactivating mtROS. Collectively, these results confirm that DON causes spleen damage by increasing mtROS, and the protective effects of curcumin.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
25d
Nerol attenuates doxorubicin-induced heart failure by inhibiting cardiomyocyte apoptosis in rats. (PubMed, Eur J Pharmacol)
Nerol plays a positive role in alleviating DOX-induced heart failure in rats, possibly by inhibiting cardiomyocyte apoptosis. These findings provide novel evidence and potential targets for developing new cardioprotective drugs.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
doxorubicin hydrochloride
27d
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism. (PubMed, Lymphatics)
Findings that robust CLL cycling associates with progressively decreasing BCL2 protein that directly correlates with decreasing venetoclax susceptibility, combined with past findings that these cycling cells have the greatest potential for activation-induced cytosine deaminase (AICDA)-driven mutations, suggest that venetoclax treatment should be accompanied by modalities that selectively target the cycling compartment without eliciting further mutations. The employment of survivin inhibitors might be such an approach.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BIRC5 (Baculoviral IAP repeat containing 5) • TLR9 (Toll Like Receptor 9) • IL15 (Interleukin 15) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR16-1 (MicroRNA 16-1)
|
BCL2 expression
|
Venclexta (venetoclax) • sepantronium bromide (PC-002)